Search results
Results from the WOW.Com Content Network
Discoid lupus erythematosus (DLE) is an uncommon autoimmune disease of the basal cell layer of the skin. It occurs in humans [1] and cats, more frequently occurring in dogs. It was first described in dogs by Griffin and colleagues in 1979. [2] [3] DLE is one form of cutaneous lupus erythematosus (CLE). DLE occurs in dogs in two forms: a ...
Dogs suffering from autoimmune diseases of the skin may experience a variety of symptoms, including persistent itching and scratching, lesions, wounds, blisters, and other skin damage, as well as loss of skin pigment. [5] Two cases of autoimmune diseases that are often found include Discoid lupus erythematosus (DLE) and Pemphigus.
The endocrine organs of the dog. Diabetes mellitus in dogs is type 1, or insulin dependent diabetes: a lack of insulin production due to destruction of pancreatic beta cells. [87] [88] [89] Current research indicates no evidence of type 2 diabetes in dogs. [90] Among the causes of diabetes mellitus in dogs are autoimmune disease or severe ...
Lupus, formally called systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] Symptoms vary among people and may be mild to severe. [1]
Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. [1] Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs. The most common and most severe form is systemic lupus erythematosus.
For premium support please call: 800-290-4726 more ways to reach us
Reactivation of these viruses is associated with sequential flare-ups in symptoms, a prolonged course, and increased disease severity which includes significant organ involvement and the development of certain autoimmune diseases viz., systemic lupus erythematosus, autoimmune thyroiditis, and type 1 diabetes mellitus. While these viral ...
The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...